InvestorsHub Logo
Followers 72
Posts 6896
Boards Moderated 0
Alias Born 12/07/2011

Re: scottsmith post# 214068

Wednesday, 01/24/2018 11:31:38 PM

Wednesday, January 24, 2018 11:31:38 PM

Post# of 403039
Here is exact quote from Feb 10 PR
So the scientists at DF involved with the phase 1 URGED IPIX TO SELECT THEM FOR FUTURE TRIALS. That’s pretty cool SS.


“For Cellceutix, there is a lot of activity going on in Texas. Elsewhere, when we mentioned the bioavailability achieved in oral Kevetrin to scientists at our previous Phase 1 clinical site, they commented that it could represent a significant improvement to lengthy or frequent intravenous infusions and urged us to select them as a site for future Kevetrin trials. That is very encouraging, as they are some of the most respected and experienced investigators in the world,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “The Company is taking a major step not only toward developing a potent new cancer drug, but one that may become the first ever shown to safely modulate p53, with the added benefit of oral delivery.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News